ABBV-622 / AbbVie - LARVOL DELTA

Pre-clinical development of a masked tumor activated nectin-4 conditional IL-15 immuno-cytokine (ABBV-622) (AACR 2025) - "The hypothesis that tumor targeted IL-15 will enhance anti-tumor efficacy is supported by data that demonstrates ~ 80 % complete response rate of intravesicular Anktiva® in bladder cancer. Additionally, nectin-4 has also emerged as a promising target for patients with bladder cancer as PADCEV® recently received accelerated approval from the FDA...AbbVie participated in the interpretation of data, review, and approval of the publication. No honoraria or payments were made for authorship."

Late-breaking abstract • Preclinical • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • IFNG • IL15 • NECTIN4 • STAT5 • STAT5AWqe